Imaging test using a HER2-targeting tracer
Part of Cancer clinical trials.
This trial studies an imaging tracer that targets HER2, a protein that can be found in certain cancers. It may help doctors see where HER2-positive tumors are in the body using scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old, and able to do daily activities fairly well (ECOG 0–1).
- Your tumor is HER2-positive or possibly HER2-positive.
- Your CT or MRI shows at least one measurable spot that can be tracked.
- You are expected to live at least 12 weeks.
- You can stay still during scan procedures for about 30 minutes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/CT scan to see if your bladder cancer has HER2 proteins, which can help predict how well you will respond to a targeted antibody-drug conjugate treatment. It is for people with advanced bladder cancer who have already tried certain standard therapies.
This study is testing a new type of PET scan that uses a special molecule (68Ga-Her2-affibody) to find tumors that have high levels of HER2. It may help doctors better see where your cancer is and decide on the best treatment.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Hear when a new HER2 Positive or Suspicious Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.